Anbio Biotechnology (NASDAQ:NNNN) Short Interest Down 44.9% in August

Anbio Biotechnology (NASDAQ:NNNN) was the recipient of a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 26,210 shares, a decline of 44.9% from the July 30th total of 47,525 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 49,980 shares, the short-interest ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Anbio Biotechnology Price Performance

NNNN traded down $0.11 on Friday, reaching $7.67. The stock had a trading volume of 252,350 shares, compared to its average volume of 159,615. The firm has a 50-day moving average of $10.51 and a 200-day moving average of $20.04. Anbio Biotechnology has a fifty-two week low of $6.61 and a fifty-two week high of $51.33.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.